Title | SARS-CoV-2 infection causes dopaminergic neuron senescence. |
Publication Type | Journal Article |
Year of Publication | 2024 |
Authors | Yang, L, Kim, TWan, Han, Y, Nair, MS, Harschnitz, O, Zhu, J, Wang, P, Koo, SYeon, Lacko, LA, Chandar, V, Bram, Y, Zhang, T, Zhang, W, He, F, Pan, C, Wu, J, Huang, Y, Evans, T, van der Valk, P, Titulaer, MJ, Spoor, JKH, O'Brien, RLFurler, Bugiani, M, Van de Berg, WDJ, Schwartz, RE, Ho, DD, Studer, L, Chen, S |
Journal | Cell Stem Cell |
Date Published | 2024 Jan 10 |
ISSN | 1875-9777 |
Abstract | COVID-19 patients commonly present with signs of central nervous system and/or peripheral nervous system dysfunction. Here, we show that midbrain dopamine (DA) neurons derived from human pluripotent stem cells (hPSCs) are selectively susceptible and permissive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection of DA neurons triggers an inflammatory and cellular senescence response. High-throughput screening in hPSC-derived DA neurons identified several FDA-approved drugs that can rescue the cellular senescence phenotype by preventing SARS-CoV-2 infection. We also identified the inflammatory and cellular senescence signature and low levels of SARS-CoV-2 transcripts in human substantia nigra tissue of COVID-19 patients. Furthermore, we observed reduced numbers of neuromelanin+ and tyrosine-hydroxylase (TH)+ DA neurons and fibers in a cohort of severe COVID-19 patients. Our findings demonstrate that hPSC-derived DA neurons are susceptible to SARS-CoV-2, identify candidate neuroprotective drugs for COVID-19 patients, and suggest the need for careful, long-term monitoring of neurological problems in COVID-19 patients. |
DOI | 10.1016/j.stem.2023.12.012 |
Alternate Journal | Cell Stem Cell |
PubMed ID | 38237586 |